The role of factor Xa inhibitors for treatment of acute venous thromboembolism (VTE) among patients with severe renal impairment is not well-established, as these patients were excluded from clinical trials.

Our study, which evaluated the safety of apixaban compared to warfarin for VTE treatment in patients with severe renal impairment, observed similar rates of bleeding events between groups.

Apixaban and warfarin demonstrated similar effectiveness, with no significant differences noted with regard to time to recurrent VTE or incidence of recurrent VTE.

These findings provide encouraging evidence to support the use of apixaban for treatment of acute VTE in patients with severe renal impairment in accordance with package insert dosing recommendations.